Inhibikase Therapeutics Inc (IKT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Inhibikase Therapeutics Inc stock (IKT) is currently trading at $1.63. Inhibikase Therapeutics Inc PS ratio (Price-to-Sales) is 1000000.00. Analyst consensus price target for IKT is $8.00. WallStSmart rates IKT as Sell.
- IKT PE ratio analysis and historical PE chart
- IKT PS ratio (Price-to-Sales) history and trend
- IKT intrinsic value — DCF, Graham Number, EPV models
- IKT stock price prediction 2025 2026 2027 2028 2029 2030
- IKT fair value vs current price
- IKT insider transactions and insider buying
- Is IKT undervalued or overvalued?
- Inhibikase Therapeutics Inc financial analysis — revenue, earnings, cash flow
- IKT Piotroski F-Score and Altman Z-Score
- IKT analyst price target and Smart Rating
Inhibikase Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Inhibikase Therapeutics Inc (IKT) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Inhibikase Therapeutics Inc (IKT) Key Strengths (1)
78.75% of shares held by major funds and institutions
Supporting Valuation Data
Inhibikase Therapeutics Inc (IKT) Areas to Watch (5)
Company is destroying shareholder value
Revenue declining -100.00%, a shrinking business
Very expensive at 1000000.0x annual revenue
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Supporting Valuation Data
Inhibikase Therapeutics Inc (IKT) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (1000000.00), Price/Book (2.99) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -97.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -97.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IKT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IKT's Price-to-Sales ratio of 1000000.00x sits near its historical average of 1000000x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 1000000x set in Feb 2026, and 0% above its historical low of 1000000x in Feb 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Inhibikase Therapeutics Inc (IKT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Inhibikase Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 1 with 100% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 762600900% of revenue (8M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -11M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Inhibikase Therapeutics Inc.
Bottom Line
Inhibikase Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(6 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:27:10 AM
About Inhibikase Therapeutics Inc(IKT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia.